Human oncogenic viruses and cancer

Current Science

Volumn 107, Issue 5, 2014, Pages 768-785

  Ahuja, Richa ^a   Jamal, Azfar ^a   Nosrati, Nagisa ^a   Pandey, Vijaya ^a   Rajput, Pallavi ^a   Saxena, Nehul ^a   Sidhu, Kaveri ^a   Kumar, Vijay ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Cancer; Cell transformation; Mitogenic signalling; Tumour virus; Viral integration

Indexed keywords

EID: 84906968800     PISSN: 00113891     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (142)

1. Zur Hausen, H., The search for infectious causes of human cancers: where and why. Virology, 2009, 392, 1-10.
2. IARC monographs on the evaluation of carcinogenic risks to humans. Biological agents vol. 100B, World Health Organization, 2012; http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B.pdf
3. Moore, P. S. and Chang, Y., Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nature Rev. Cancer, 2010, 10, 878-889.
4. Banks, L., Pim, D. and Thomas, M., Human tumour viruses and the deregulation of cell polarity in cancer. Nature Rev. Cancer, 2012, 12, 877-886.
5. Gross, L., Oncogenic Viruses, Pergamon Press, Oxford, 1970.
6. Epstein, M. A., Achong, B. G. and Barr, Y. M., Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet, 1964, 1, 702-703.
7. Dane, D. S., Cameron, C. H. and Briggs, M., Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet, 1970, 1, 695-698.
8. Sherr, C. J., Principles of tumor suppression. Cell, 2004, 116, 235-246.
9. Young, L. S. and Rickinson, A. B., Epstein-Barr virus: 40 years on. Nature Rev. Cancer, 2004, 4, 757-768.
10. Mosialos, G., Birkenbach, M., Yalamanchili, R., Vanarsdale. T., Ware, C. and Kieff, E., The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell, 1995, 80, 389-399.
11. Kilger, E., Kieser, A., Baumann, M. and Hammerschmidt, W., Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J., 1998, 17, 1700-1709.
12. Mesri, E. A., Cesarman, E. and Boshoff, C., Kaposi's sarcoma and its associated herpesvirus. Nature Rev. Cancer, 2010, 10, 707-719.
13. Doorbar, J., Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci., 2006, 110, 525-541.
14. Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C. and Wacholder, S., Human papillomavirus and cervical cancer. Lancet, 2007, 370, 890-907.
15. Miller, R. W. and Rabkin, C. S., Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol. Biomarkers Prev., 1999, 8, 153-158.
16. Chang, Y. and Moore, P. S., Merkel cell carcinoma: a virusinduced human cancer. Annu. Rev. Pathol., 2012, 7, 123-144.
17. Seeger, C. and Mason, W. S., Hepatitis B virus biology. Microbiol. Mol. Biol. Rev., 2000, 64, 51-68.
18. Guidotti, L. G. and Chisari, F. V., Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol., 2006, 1, 23-61.
19. Scheel, T. K. and Rice, C. M., Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Med., 2013, 19, 837-849.
20. Kannian, P. and Green, P. L., Human T lymphotropic virus type 1 (HTLV-1): molecular biology and oncogenesis. Viruses, 2010, 2, 2037-2077.
21. Boxus, M. and Willems, L., Mechanisms of HTLV-1 persistence and transformation. Br. J. Cancer, 2009, 101, 1497-1501.
22. Stevenson, M., HIV-1 pathogenesis. Nature Med., 2003, 9, 853-860.
23. Saha, A., Kaul, R., Murakami, M. and Robertson, E. S., Tumor viruses and cancer biology: modulating signaling pathways for therapeutic intervention. Cancer Biol. Ther., 2010, 15, 961-978.
24. Kumar, V. and Sarkar, D. P., Hepatitis B virus X protein (HBx): structure-function relationships and role in viral pathogenesis. In Handbook of Experimental Pharmacology (eds Triezenberg, S. J., Kaufman, J. and Gossen, M.), Springer Verlag, Germany, 2004, pp. 377-407.
25. Hassan, M., Ghozlan, H. and Abdel-Kader, O., Activation of c-Jun NH2-terminal kinase (JNK) signaling pathway is essential for the stimulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)-mediated cell growth. Virology, 2005, 333, 324-336.
26. Pan, H., Xie, J., Ye, F. and Gao S. J., Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection. J. Virol., 2006, 80, 5371-5382.
27. Zhu, X., Zhou, F., Qin, D., Zeng, Y., Lv, Z., Yao, S. and Lu, C., Human immunodeficiency virus type 1 induces lytic cycle replication of Kaposi's-sarcoma-associated herpesvirus: role of Ras/c-Raf/MEK1/2, PI3K/AKT, and NF-κB signaling pathways. J. Mol. Biol., 2011, 410, 1035-1051.
28. Chen, H., Hutt-Fletcher, L., Cao, L. and Hayward, S. D., A positive auto-regulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. J. Virol., 2003, 77, 4139-4148.
29. Nakamura, N. et al., Human T-cell leukemia virus type 1 Tax protein induces the expression of STAT1 and STAT5 genes in T-cells. Oncogene, 1999, 18, 2667-2675.
30. Osborne, J., Moore, P. S. and Chang, Y., KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum. Immunol., 1999, 60, 921-927.
31. Zeng, Y. et al., Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi's sarcomaassociated herpesvirus: role of JAK/STAT signaling. J. Virol., 2007, 81, 2401-2417.
32. Yamaguchi, T. et al., Phosphorylated Smad2 and Smad3 signaling: shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C. Hepatol. Res., 2013 [Epub ahead of print].
33. Choi, S. H. and Hwang, S. B., Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein. J. Biol. Chem., 2006, 281, 7468-7478.
34. Prokova, V., Mosialos, G. and Kardassis, D., Inhibition of transforming growth factor beta signaling and Smad-dependent activation of transcription by the latent membrane protein 1 of Epstein-Barr virus. J. Biol. Chem., 2002, 277, 9342-9350.
35. Hypes, M. K., Pirisi, L. and Creek, K. E., Mechanisms of decreased expression of transforming growth factor-beta receptor type I at late stages of HPV16-mediated transformation. Cancer Lett., 2009, 282, 177-186.
36. Hall, W. W. and Fujii, M., Deregulation of cell-signaling pathways in HTLV-1 infection. Oncogene, 2005, 24, 5965-5975.
37. Liu, Y., Sun, R., Lin, X., Liang, D., Deng, Q. and Lan, K., Kaposi's sarcoma-associated herpesvirus-encoded microRNA miR-K12-11 attenuates transforming growth factor beta signaling through suppression of SMAD5. J. Virol., 2012, 86, 1372-1381.
38. Byg, L. M., Vidlund, J., Vasiljevic, N., Clausen, D., Forslund, O. and Norrild, B., NF-κB signalling is attenuated by the E7 protein from cutaneous human papillomaviruses. Virus Res., 2012, 169, 48-53.
39. de Oliveira, D. E., Ballon, G. and Cesarman, E., NF-kappaB signaling modulation by EBV and KSHV. Trends Microbiol., 2010, 18, 248-257.
40. Cheng, H., Ren, T. and Sun, S. C., New insight into the oncogenic mechanism of the retroviral oncoprotein Tax. Protein Cell, 2012, 3, 581-589.
41. Arsura, M. and Cavin, L. G., Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett., 2005, 229, 157-169.
42. Cheng, F., Pekkonen, P. and Ojala, P. M., Instigation of Notch signaling in the pathogenesis of Kaposi's sarcoma-associated herpesvirus and other human tumor viruses. Future Microbiol., 2012, 7, 1191-1205.
43. Wang, F., Zhou, H., Yang, Y., Xia, X., Sun, Q., Luo, J. and Cheng, B., Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncol. Rep., 2012, 27, 1170-1176.
44. Hayward, S. D., Liu, J. and Fujimuro, M., Notch and Wnt signaling: mimicry and manipulation by gamma herpesviruses. Sci. STKE, 2006, 2006, re4.
45. Hsieh, A., Kim, H. S., Lim, S. O., Yu, D. Y. and Jung, G., Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/?-catenin signaling. Cancer Lett., 2011, 300, 162-172.
46. Rampias, T., Boutati, E., Pectasides, E., Sasaki, C., Kountourakis, P., Weinberger, P. and Psyrri, A., Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol. Cancer Res., 2010, 8, 433-443.
47. Arzumanyan, A. et al., Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein. Cancer Res., 2012, 72, 5912-5920.
48. Pereira, Tde. A. et al., Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab. Invest., 2010, 90, 1690-1703.
49. Samarzija, I. and Beard, P., Hedgehog pathway regulators influence cervical cancer cell proliferation, survival and migration. Biochem. Biophys. Res. Commun., 2012, 425, 64-69.
50. Dayaram, T. and Marriott, S. J., Effect of transforming viruses on molecular mechanisms associated with cancer. J. Cell Physiol., 2008, 216, 309-314.
51. Fuentes-Gonza´lez, A. M., Contreras-Paredes, A., Manzo-Merino, J. and Lizano, M., The modulation of apoptosis by oncogenic viruses. Virol. J., 2013, 10, 182.
52. Martin, D. and Gutkind, J. S., Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene, 2008, 27, S31-42.
53. Fan, X., Liu, Y., Heilman, S. A. and Chen, J. J., Human papillomavirus E7 induces rereplication in response to DNA damage. J. Virol., 2013, 87, 1200-1210.
54. Pandey, V. and Kumar, V., HBx protein of hepatitis B virus promotes reinitiation of DNA replication by regulating expression and intracellular stability of replication licensing factor CDC6. J. Biol. Chem., 2012, 287, 20545-20554.
55. Rakotomalala, L., Studach, L., Wang, W. H., Gregori, G., Hullinger, R. L. and Andrisani O., Hepatitis B virus X protein increases the Cdt1-to-geminin ratio inducing DNA re-replication and polyploidy. J. Biol. Chem., 2008, 283, 28729-28740.
56. Nikitin, P. A. and Luftig, M. A., The DNA damage response in viral-induced cellular transformation. Br. J. Cancer, 2012, 106, 429-435.
57. Wang, W. H., Hullinger, R. L. and Andrisani, O. M., Hepatitis B virus X protein via the p38MAPK pathway induces E2F1 release and ATR kinase activation mediating p53 apoptosis. J. Biol. Chem., 2008, 283, 25455-25467.
58. Choudhuri, T., Verma, S. C., Lan, K., Murakami, M. and Robertson, E. S., The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J. Virol., 2007, 81, 6718-6730.
59. Liu, B., Hong, S., Tang, Z., Yu, H. and Giam, C. Z., HTLV-I Tax directly binds the Cdc20-associated anaphase-promoting complex and activates it ahead of schedule. Proc. Natl. Acad. Sci. USA, 2005, 102, 63-68.
60. Korzeniewski, N., Soaedy, N., Duensing, S. and Duensing, S., Genomic instability and cancer: lessons learned from human papillomaviruses. Cancer Lett., 2011, 305, 113-122.
61. Poreba, E., Broniarczyk, J. K. and Gozdzicka-Jozefiak, A., Epigenetic mechanisms in virus-induced tumorigenesis. Clin. Epigenet., 2011, 2, 233-247.
62. McLaughlin-Drubin, M. E. and Munger, K., Biochemical and functional interactions of human papillomavirus proteins with polycomb group proteins. Viruses, 2013, 5, 1231-1249.
63. Shuda, M., Kwun, H. J., Feng, H., Chang, Y. and Moore, P. S., Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J. Clin. Invest., 2011, 121, 3623-3634.
64. Beisser, P. S. et al., The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase. J. Virol., 2005, 79, 441-449.
65. Burysek, L. and Pitha, P. M., Latently expressed human herpesvirus 8-encoded interferon regulatory factor 2 inhibits doublestranded RNA-activated protein kinase. J. Virol., 2001, 75, 2345-2352.
66. Gale Jr, M. et al., Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell Biol., 1998, 18, 5208-5218.
67. Mack, H. I. D. and Munger, K., Modulation of autophagy-like processes by tumor viruses. Cells, 2012, 1, 204-247.
68. Holland, E. C., Sonenberg, N., Pandolfi, P. P. and Thomas, G., Signaling control of mRNA translation in cancer pathogenesis. Oncogene, 2004, 23, 3138-3144.
69. Oh, K. J., Kalinina, A., Park, N. H. and Bagchi, S., Deregulation of eIF4E: 4E-BP1 in differentiated human papillomaviruscontaining cells leads to high levels of expression of the E7 oncoprotein. J. Virol., 2006, 80, 7079-7088.
70. Raychaudhuri, S., Fontanes, V., Barat, B. and Dasgupta, A., Activation of ribosomal RNA transcription by hepatitis C virus involves upstream binding factor phosphorylation via induction of cyclin D1. Cancer Res., 2009, 69, 2057-2064.
71. Blenis, J. and Erikson, R. L., Phosphorylation of the ribosomal protein S6 is elevated in cells transformed by a variety of tumor viruses. J. Virol., 1984, 50, 966-969.
72. Sarek, G. et al., Nucleophosmin phosphorylation by v-cyclin- CDK6 controls KSHV latency. PLoS Pathog., 2010, 6, e1000818.
73. Boisvert, F. M., van Koningsbruggen, S., Navascue´s, J. and Lamond, A. I., The multifunctional nucleolus. Nature Rev. Mol. Cell Biol., 2007, 8, 574-585.
74. Hein, N., Hannan, K. M., George, A. J., Sanij, E. and Hannan, R. D., The nucleolus: an emerging target for cancer therapy. Trends Mol. Med., 2013 [Epub ahead of print].
75. Greco, A., Involvement of the nucleolus in replication of human viruses. Rev. Med. Virol., 2009, 19, 201-214.
76. Kapoor, N. R., Ahuja, R., Shukla, S. K. and Kumar, V., The HBx protein of hepatitis B virus confers resistance against nucleolar stress and anti-cancer drug-induced p53 expression. FEBS Lett., 2013, 587, 1287-1292.
77. Weissman, A. M., Shabek, N. and Ciechanover, A., The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nature Rev. Mol. Cell. Biol., 2011, 12, 605-620.
78. Isaacson, M. K. and Ploegh, H. L., Ubiquitination, ubiquitin-like modifiers, and deubiquitination in viral infection. Cell Host Microbe, 2009, 5, 559-570.
79. Saxena, N. and Kumar, V., Oncogenic viruses: DUBbing their way to cancer. Virol. Discov., 2013; doi:10.7243/2052-6202-1-5.
80. Keller, S., Sanderson, M. P., Stoeck, A. and Altevogt, P., Exosomes: from biogenesis and secretion to biological function. Immunol. Lett., 2006, 107, 102-108.
81. Flanagan, J., Middeldorp, J. and Sculley, T., Localization of the Epstein-Barr virus protein LMP 1 to exosomes. J. Gen. Virol., 2003, 84, 1871-1879.
82. Pegtel, D. M. et al., Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. USA, 2010, 107, 6328-6333.
83. Izquierdo-Useros, N., Naranjo-Go´mez, M., Erkizia, I., Puertas, M. C., Borra`s, F. E., Blanco, J. and Martinez-Picado, J., HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse? PLoS Pathog., 2010, 6, e1000740.
84. Lenassi, M. et al., HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic, 2010, 11, 110-122.
85. Mack, M. et al., Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. Nature Med., 2000, 6, 769-775.
86. Rozmyslowicz, T. et al., Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS, 2003, 17, 33-42.
87. Tamai, K. et al., Regulation of hepatitis C virus secretion by the Hrs-dependent exosomal pathway. Virology, 2012, 422, 377-385.
88. Sherr, C. J. and McCormick, F., The RB and p53 pathways in cancer. Cancer Cell, 2002, 2, 103-112.
89. Cai, Q. L., Knight, J. S., Verma, S. C., Zald, P. and Robertson, E. S., EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog., 2006, 2, 116.
90. Knight, J. S., Sharma, N. and Robertson, E. S., SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol. Cell. Biol., 2005, 25, 1749-1763.
91. Yi, F. et al., Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology, 2009, 388, 236-247.
92. Kalra, N. and Kumar, V., The X protein of hepatitis B virus binds to the F box protein Skp2 and inhibits the ubiquitination and proteasomal degradation of c-Myc. FEBS Lett., 2006, 580, 431-436.
93. Parroche, P. et al., Human papillomavirus type 16 E6 inhibits p21(WAF1) transcription independently of p53 by inactivating p150(Sal2). Virology, 2011, 417, 443-448.
94. Helt, A. M. and Galloway, D. A., Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis, 2003, 24, 159-169.
95. Zhang, L., Zhi, H., Liu, M., Kuo, Y. L. and Giam, C. Z., Induction of p21(CIP1/WAF1) expression by human T-lymphotropic virus type 1 Tax requires transcriptional activation and mRNA stabilization. Retrovirology, 2009, 6, 35.
96. Iwahori, S. et al., Phosphorylation of p27Kip1 by Epstein-Barr virus protein kinase induces its degradation through SCFSkp2 ubiquitin ligase actions during viral lytic replication. J. Biol. Chem., 2009, 284, 18923-18931.
97. Yao, Z. Q., Eisen-Vandervelde, A., Ray, S. and Hahn, Y. S., HCV core/gC1qR interaction arrests T cell cycle progression through stabilization of the cell cycle inhibitor p27Kip1. Virology, 2003, 314, 271-282.
98. Mukherji, A., Janbandhu, V. C. and Kumar, V., HBx-dependent cell cycle deregulation involves interaction with cyclin E/A-cdk2 complex and destabilization of p27Kip1. Biochem. J., 2007, 401, 247-256.
99. O'Nions, J. and Allday, M. J., Deregulation of the cell cycle by the Epstein-Barr virus. Adv. Cancer Res., 2004, 92, 119-186.
100. Chowdhury, I. H., Farhadi, A., Wang, X. F., Robb, M. L., Birx, D. L. and Kim, J. H., Human T-cell leukemia virus type 1 Tax activates cyclin-dependent kinase inhibitor p21/Waf1/Cip1 expression through a p53-independent mechanism: Inhibition of cdk2. Int. J. Cancer, 2003, 107, 603-611.
101. Skalska, L., White, R. E., Franz, M., Ruhmann, M. and Allday, M. J., Epigenetic repression of p16(INK4A) by latent Epstein- Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog., 2010, 6, e1000951.
102. Cai, Q. et al., Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathog., 2011, 7, e1002418.
103. Saha, A. et al., Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog., 2011, 7, e1001275.
104. Huang, Y., Ohtani, K., Iwanaga, R., Matsumura, Y. and Nakamura, M., Direct trans-activation of the human cyclin D2 gene by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene, 2001, 20, 1094-1102.
105. Kim, Y. M., Geiger, T. R., Egan, D. I., Sharma, N. and Nyborg, J. K., The HTLV-1 tax protein cooperates with phosphorylated CREB, TORC2 and p300 to activate CRE-dependent cyclin D1 transcription. Oncogene, 2010, 29, 2142-2152.
106. Dittmer, D. P. and Krown, S. E., Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr. Opin. Oncol., 2007, 19, 452-457.
107. Weinberg, R. A., Oncogenes, anti-oncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res., 1989, 49, 3713-3721.
108. Radkov, S., Kellam, P. and Boshoff, C., The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma- E2F pathway and with the oncogene Hras transforms primary rat cells. Nature Med., 2000, 6, 1121-1127.
109. Jayachandra, S., Low, K. G., Thlick, A.-E., Yu, J., Ling, P. D., Chang, Y. and Moore, P. S., Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. Proc. Natl. Acad. Sci. USA, 1999, 96, 11566-11571.
110. Anderton, E., Yee, J., Smith, P., Crook, T., White, R. E. and Allday, M. J., Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene, 2008, 27, 421-433.
111. Veldman, T., Liu, X., Yuan, H. and Schlegel, R., Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. USA, 2003, 100, 8211-8216.
112. Feitelson, M. A., c-myc overexpression in hepatocarcinogenesis. Hum. Pathol., 2004, 35, 1299-1302.
113. Liu, H., Shi, W., Luan, F., Xu, S., Yang, F., Sun, W. and Ma, C., Hepatitis B virus X protein up-regulates transcriptional activation of human telomerase reverse transcriptase. Virus Genes, 2010, 40, 174-182.
114. Shukla, S. K. and Kumar, V., Hepatitis B virus X protein and c-Myc cooperate in the upregulation of ribosome biogenesis and in cellular transformation. FEBS J., 2012, 279, 3859-3871.
115. Ray, R. B., Lagging, L. M., Meyer, K. and Ray, R., Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J. Virol., 1996, 70, 4438-4443.
116. Annunziata, C., Buonaguro, L., Buonaguro, F. M. and Tornesello, M. L., Characterization of the human papillomavirus (HPV) integration sites into genital cancers. Pathol. Oncol. Res., 2012, 18, 803-808.
117. Thorland, E. C., Myers, S. L., Gostout, B. S. and Smith, D. I., Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene, 2003, 22, 1225-1237.
118. Sung, W.-K., Zheng, H., Li, S., Chen, R., Liu, X., Li, Y. and Luk, J. M., Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nature Genet., 2012, 44, 1-6.
119. Peter, M., Rosty, C., Couturier, J., Radvanyi, F., Teshima, H. and Sastre-Garau, X., MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors. Oncogene, 2006, 25, 5985-5993.
120. Ferber, M. J., Montoya, D. P., Yu, C., Aderca, I., McGee, A., Thorland, E. C. and Roberts, L. R., Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene, 2003, 22, 3813-3820.
121. Jiang, Z., Jhunjhunwala, S., Liu, J., Haverty, P. M., Kennemer, M. I., Guan, Y. and Zhang, Z., The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res., 2012, 22, 593-601.
122. Morissette, G. ad Flamand, L., Herpesviruses and chromosomal integration. J. Virol., 2010, 84, 12100-12109.
123. Li, J., Wang, X., Diaz, J., Tsang, S. H., Buck, C. B. and You, J., Merkel cell polyomavirus large T antigen disrupts host genomic integrity and inhibits cellular proliferation. J. Virol., 2013 [Epub ahead of print].
124. Gerbitz, A., Mautner, J., Geltinger, C., Ho¨rtnagel, K., Christoph, B., Asenbauer, H. and Bornkamm, G. W., Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma. Oncogene, 1999, 18, 1745-1753.
125. Derse, D., Crise, B., Li, Y., Princler, G., Lum, N., Stewart, C. and Wu, X., Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses. J. Virol., 2007, 81, 6731-6741.
126. Lam, N. and Sugden, B., LMP1, a viral relative of the TNF receptor family, signals principally from intracellular compartments. EMBO, 2003, 22, 3027-3038.
127. Graham, J. P., Arcipowski, K. M. and Bishop, G. A., Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunol. Rev., 2010, 237, 226-248.
128. Moody, C. A. and Laimins, L. A., Human papillomavirus oncoproteins: pathways to transformation. Nature Rev. Cancer, 2010, 10, 550-560.
129. Murakami, M., Kaul, R., Kumar, P. and Robertson, E. S., Nucleoside diphosphate kinase/Nm23 and Epstein-Barr virus. Mol. Cell. Biochem., 2009, 329, 131-139.
130. Dai, L., Bratoeva, M., Toole, B. P., Qin, Z. and Parsons, C., KSHV activation of VEGF secretion and invasion for endothelial cells is mediated through viral upregulation of emmprin-induced signal transduction. Int. J. Cancer, 2011, 131, 834-844.
131. National Cancer Institute at the National Institutes of Health, USA; http://www.cancer.gov/search/results
132. Huang, L. M., Lu, C. Y. and Chen, D. S., Hepatitis B virus infection, its sequelae, and prevention by vaccination. Curr. Opin. Immunol. 2011, 23, 237-243
133. Jin, X. W., Lipold, L., Sikon, A. and Rome, E., Human papillomavirus vaccine: safe, effective, underused. Cleve. Clin. J. Med., 2013, 80, 49-60.
134. Bishop, G. A. and Busch, L. K., Molecular mechanisms of B-lymphocyte transformation by Epstein-Barr virus. Microbes Infect., 2002, 4, 853-857.
135. Frappier, L., Contributions of Epstein-Barr Nuclear antigen 1 (EBNA1) to cell immortalization and survival. Viruses, 2012, 4, 1537-1547.
136. Chemin, I. and Zoulim, F., Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett., 2009, 286, 52-59.
137. Feng, H., Shuda, M., Chang, Y. and Moore, P. S., Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science, 2008, 319, 1096-1100.
138. Swain, A. and Coffin, J. M., Mechanism of transduction by retroviruses. Science, 1992, 255, 841-845.
139. Hunter, T. and Sefton, B. M., Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl. Acad. Sci. USA, 1980, 77, 1311-1315.
140. Hung, F. and Chassidy, J., Insertional oncogenesis by non-acute retroviruses: implications for gene therapy. Viruses, 2011, 3, 398-422.
141. Grassmann, R., Aboud, M. and Jeang, T. K., Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene, 2005, 24, 5976-5985.
142. McGriven, D. and Lemon, S., Tumor suppressors, chromosomal instability and hepatitis C virus associated liver cancer. Annu. Rev. Pathol., 2009, 4, 399-415.